IL-28B down-regulates regulatory t cells but does not improve the protective immunity following tuberculosis subunit vaccine immunization

International Immunology

Volumn 28, Issue 2, 2016, Pages 77-85

  Luo, Yanping ^a   Ma, Xingming ^a   Liu, Xun ^a   Lu, Xiaoling ^a   Niu, Hongxia ^a   Yu, Hongjuan ^a   Bai, Chunxiang ^a   Peng, Jinxiu ^a   Xian, Qiaoyang ^b   Wang, Yong ^b   Zhu, Bingdong ^a  

^a LANZHOU UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Cytokine; Il 28b; Immune regulation; Regulatory t cells; Tuberculosis vaccine

Indexed keywords

INTERLEUKIN 28B; SUBUNIT VACCINE; TUBERCULOSIS SUBUNIT VACCINE; UNCLASSIFIED DRUG; BCG VACCINE; INTERFERON; INTERFERON-LAMBDA3, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; DOWN REGULATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ADENOVIRIDAE; ANIMAL; BACTERIAL LOAD; C57BL MOUSE; GENETICS; HUMAN; IMMUNITY; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; TH1 CELL; TUBERCULOSIS;

ADENOVIRIDAE; ANIMALS; BACTERIAL LOAD; FEMALE; HUMANS; IMMUNITY; INTERFERONS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 84961775749     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxv061     Document Type: Article

References (42)

1. Fine, P. E. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339.
2. Schön, T., Lerm, M. and Stendahl, O. 2013. Shortening the 'short-course' therapy- insights into host immunity may contribute to new treatment strategies for tuberculosis. J. Intern. Med. 273:368.
3. Rouanet, C., Debrie, A. S., Lecher, S. and Locht, C. 2009. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect. 11:995.
4. Trunz, B. B., Fine, P. and Dye, C. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367:1173.
5. Abel, B., Tameris, M., Mansoor, N. et al. 2010. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am. J. Respir. Crit. Care Med. 181:1407.
6. Billeskov, R., Elvang, T. T., Andersen, P. L. and Dietrich, J. 2012. The HyVac4 subunit vaccine efficiently boosts BCG-primed antimycobacterial protective immunity. PLoS One 7:e39909.
7. Day, C. L., Tameris, M., Mansoor, N. et al. 2013. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am. J. Respir. Crit. Care Med. 188:492.
8. Luo, Y., Wang, B., Hu, L. et al. 2009. Fusion protein Ag85BMPT64 (190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Vaccine 27:6179.
9. Cooper, A. M. 2009. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27:393.
10. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. and Toda, M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.
11. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531.
12. O'Garra, A. and Vieira, P. 2004. Regulatory T cells and mechanisms of immune system control. Nat. Med. 10:801.
13. Joosten, S. A. and Ottenhoff, T. H. 2008. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum. Immunol. 69:760.
14. Ordway, D., Henao-Tamayo, M., Harton, M. et al. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 179:522.
15. Ordway, D. J., Shang, S., Henao-Tamayo, M. et al. 2011. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin. Vaccine Immunol. 18:1527.
16. Fletcher, H. A., Pathan, A. A., Berthoud, T. K. et al. 2008. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1. Vaccine 26:5269.
17. Fedatto, P. F., Sergio, C. A., Paula, M. O. et al. 2012. Protection conferred by heterologous vaccination against tuberculosis is dependent on the ratio of CD4(+) /CD4(+) Foxp3(+) cells. Immunology 137:239.
18. Quinn, K. M., Rich, F. J., Goldsack, L. M., de Lisle, G. W., Buddle, B. M., Delahunt, B. and Kirman, J. R. 2008. Accelerating the secondary immune response by inactivating CD4(+)CD25(+) T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis. Eur. J. Immunol. 38:695.
19. Witte, K., Witte, E., Sabat, R. and Wolk, K. 2010. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 21:237.
20. Donnelly, R. P. and Kotenko, S. V. 2010. Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res. 30:555.
21. Morrow, M. P., Pankhong, P., Laddy, D. J., Schoenly, K. A., Yan, J., Cisper, N. and Weiner, D. B. 2009. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113:5868.
22. Morrow, M. P., Yan, J., Pankhong, P. et al. 2010. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin. Vaccine Immunol. 17:1493.
23. Xin, Q., Niu, H., Li, Z. et al. 2013. Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PLoS One 8:e72745.
24. Niu, H., Peng, J., Bai, C. et al. 2015. Multi-stage tuberculosis subunit vaccine candidate LT69 provides high protection against Mycobacterium tuberculosis infection in mice. PLoS One 10:e0130641.
25. Reed, L. J. and Muench, H. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493.
26. Clausen, L. N., Weis, N., Astvad, K. et al. 2011. Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J .Viral Hepat. 18:e66.
27. Balagopal, A., Thomas, D. L. and Thio, C. L. 2010. IL28B and the control of hepatitis C virus infection. Gastroenterology 139:1865.
28. Shindo, H., Maekawa, S., Komase, K. et al. 2013. IL-28B (IFNlambda3) and IFN-alpha synergistically inhibit HCV replication. J. Viral Hepat. 20:281.
29. Charlton, M. R., Thompson, A., Veldt, B. J. et al. 2011. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53:317.
30. Chen, C., Tan, B., Zhou, Y. et al. 2012. IL-28B genetic variant is associated with the risk of schizophrenia in the Chinese Han population. DNA Cell Biol. 31:988.
31. Yoshimoto, K., Kishida, T., Nakano, H. et al. 2011. Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma. J. Immunother. 34:139.
32. Wang, N. S., McHeyzer-Williams, L. J., Okitsu, S. L., Burris, T. P., Reiner, S. L. and McHeyzer-Williams, M. G. 2012. Divergent transcriptional programming of class-specific B cell memory by T-bet and RORα. Nat. Immunol. 13:604.
33. Neubert, K., Lehmann, C. H., Heger, L. et al. 2014. Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. J. Immunol. 192:5830.
34. Matsuo, K., Okamoto, H., Kawai, Y. et al. 2014. Vaccine efficacy of transcutaneous immunization with amyloid beta using a dissolving microneedle array in a mouse model of Alzheimer's disease. J. Neuroimmunol. 266:1.
35. Jaron, B., Maranghi, E., Leclerc, C. and Majlessi, L. 2008. Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis. PLoS One 3:e2833.
36. Morse, M. A., Hobeika, A. C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H. K., and Clay, T. M. 2008. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112:610.
37. Bayry, J. 2014. Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy. Virusdisease 25:18.
38. Masopust, D., Kaech, S. M., Wherry, E. J. and Ahmed, R. 2004. The role of programming in memory T-cell development. Curr. Opin. Immunol. 16:217.
39. Shen, C. H., Talay, O., Mahajan, V. S., Leskov, I. B., Eisen, H. N. and Chen, J. 2010. Antigen-bearing dendritic cells regulate the diverse pattern of memory CD8 T-cell development in different tissues. Proc. Natl Acad. Sci. USA 107:22587.
40. de Goer de Herve, M. G., Jaafoura, S., Vallee, M., and Taoufik, Y. 2012. FoxP3(+) regulatory CD4 T cells control the generation of functional CD8 memory. Nat. Commun. 3:986.
41. Kim, C., Wilson, T., Fischer, K. F. and Williams, M. A. 2013. Sustained interactions between T cell receptors and antigens promote the differentiation of CD4+ memory T cells. Immunity 39:508.
42. Mueller, S. N., Gebhardt, T., Carbone, F. R. and Heath, W. R. 2013. Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 31:137.